FUNDAMENTALS · Fundamentals · US Healthcare

The Cooper Companies (COO) Fundamentals 2026 — P/E 59.6x, Revenue Analysis | SniperIQ

The Cooper Companies (COO) is a US-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of

3.7B, trading at $70.31 on the NASDAQ. This SniperIQ fundamentals page covers The Cooper Companies's valuation (P/E 59.6x, P/B 1.7x), profitability (net margin 5.6%), revenue ($4.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
3.7B
P/E (TTM)59.6x
Net Margin5.6%
Revenue (FY25)$4.1B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is The Cooper Companies's market cap?

The Cooper Companies (COO) has a market capitalization of approximately

3.7B, trading at $70.31 on the NASDAQ. Market cap moves with the live share price.

What is The Cooper Companies's P/E ratio?

The Cooper Companies's trailing twelve-month P/E ratio is 59.6x, with a price-to-book (P/B) of 1.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is The Cooper Companies?

The Cooper Companies runs a net profit margin of 5.6%, a gross margin of 64.4%, and an operating margin of 11.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does The Cooper Companies generate?

The Cooper Companies reported revenue of $4.1B for fiscal year 2025, with net income of

75M and earnings per share (EPS) of 1.88. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does The Cooper Companies pay a dividend?

The Cooper Companies does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is The Cooper Companies financially healthy?

The Cooper Companies carries a debt-to-equity ratio of 0.30x and a current ratio of 1.27x, with a market beta of 0.84. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is The Cooper Companies a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For The Cooper Companies (COO) the key facts are: market cap

3.7B, P/E 59.6x, revenue $4.1B, 52-week range 58.89-89.83. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track The Cooper Companies's full fundamentals live

Get The Cooper Companies's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Shenzhen Kangtai Biological Products (300601) fundamentals · Taiko Pharmaceutical (4574) fundamentals · Anhui Anke Biotechnology (Group) (300009) fundamentals · Angelalign Technology (6699) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons